Victory Capital Management Inc. Invests $953,000 in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Victory Capital Management Inc. acquired a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTXFree Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 41,240 shares of the company’s stock, valued at approximately $953,000. Victory Capital Management Inc. owned 0.07% of SpringWorks Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company’s stock valued at $37,000 after purchasing an additional 792 shares during the period. IFP Advisors Inc grew its holdings in SpringWorks Therapeutics by 31.2% during the 2nd quarter. IFP Advisors Inc now owns 2,794 shares of the company’s stock valued at $63,000 after buying an additional 665 shares in the last quarter. Osaic Holdings Inc. grew its holdings in SpringWorks Therapeutics by 42.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,609 shares of the company’s stock valued at $69,000 after buying an additional 782 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in SpringWorks Therapeutics by 64.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,122 shares of the company’s stock valued at $82,000 after buying an additional 1,222 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY grew its holdings in SpringWorks Therapeutics by 65.3% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 3,185 shares of the company’s stock valued at $84,000 after buying an additional 1,258 shares in the last quarter.

SpringWorks Therapeutics Stock Down 2.2 %

SWTX opened at $45.91 on Tuesday. The business has a fifty day moving average of $38.88 and a 200 day moving average of $29.96. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $49.98. The stock has a market cap of $2.87 billion, a P/E ratio of -9.39 and a beta of 0.82.

Wall Street Analysts Forecast Growth

SWTX has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of SpringWorks Therapeutics in a report on Monday, January 8th. HC Wainwright lifted their target price on SpringWorks Therapeutics from $52.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Guggenheim initiated coverage on SpringWorks Therapeutics in a report on Monday, February 5th. They issued a “buy” rating and a $75.00 target price for the company. The Goldman Sachs Group lifted their target price on SpringWorks Therapeutics from $47.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, November 29th. Finally, Barclays lifted their target price on SpringWorks Therapeutics from $41.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $56.67.

Check Out Our Latest Analysis on SpringWorks Therapeutics

SpringWorks Therapeutics Company Profile

(Free Report)

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors.

See Also

Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTXFree Report).

Institutional Ownership by Quarter for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.